CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Axicabtagene Ciloleucel 治疗滤泡性淋巴瘤：临床实用性、患者选择与已报告结局的当前观点
英文原题：Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes.
查看英文原题
Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Axicabtagene ciloleucel（axi-cel）是一种自体抗CD19CAR-T 细胞疗法（CAR-T），已在B细胞非霍奇金淋巴瘤中显示出疗效。即使在存在高风险特征（早期复发、重度预处理患者和巨块型疾病）的情况下，它在复发/难治性滤泡性淋巴瘤（FL）中也显示出高疗效。R/R滤泡性淋巴瘤的治疗选择无法提供长期缓解，尤其是在三线治疗中。Axi-cel在ZUMA-5研究中针对R/R FL进行了研究，该研究显示出高缓解率和持久缓解。Axi-cel与预期但可管理的毒性相关。长期随访可能有助于了解FL的潜在治愈可能性。Axi-cel应成为R/R FL二线以后标准治疗选择的一部分。
展开英文摘要原文
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor T-cell therapy (CAR-T) that has shown efficacy in B-cell non-Hodgkin's lymphoma. It has shown high efficacy in relapsed/refractory follicular lymphoma (FL) even in the presence of high risk features (early relapse, heavily pretreated patients and bulky disease).
Treatment options for R/R follicular lymphoma do not offer long-term remissions, especially in the third-line setting. Axi-cel was studied in R/R FL in the ZUMA-5 study, which showed high response rates with durable remissions. Axi-cel was associated with anticipated but manageable toxicities. Long-term follow up may be able to inform the potential for cure of FL. Axi-cel should be part of the standard of care options for R/R FL beyond second line.
论文信息
- 作者
- Mohty R、Kharfan-Dabaja MA、Chavez JC
- 第一作者单位
- Department of Blood and Marrow Transplantation and Cellular Therapy, Moffitt Cancer Center, Tampa, FL, USA.United States
- 通讯作者单位
- Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA.United States
- 文献类型
- 综述
- 期刊
- Cancer management and research2023
- 原文标识
- PubMed 37155519 · DOI 10.2147/CMAR.S368588
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →